Conflicts of interest MAJ has received funding from Merck-Serono to attend an international conference. The offer of support post dated the experimental timeframe and manuscript submission.
Anti-lymphocyte function associated antigen-1 inhibits T-helper 2 function of human allergen-specific CD4+ T cells
Article first published online: 17 JAN 2008
© 2008 The Authors
British Journal of Dermatology
Volume 158, Issue 3, pages 456–462, March 2008
How to Cite
Ardern-Jones, M.R., Black, A.P. and Ogg, G.S. (2008), Anti-lymphocyte function associated antigen-1 inhibits T-helper 2 function of human allergen-specific CD4+ T cells. British Journal of Dermatology, 158: 456–462. doi: 10.1111/j.1365-2133.2007.08393.x
- Issue published online: 17 JAN 2008
- Article first published online: 17 JAN 2008
- Accepted for publication 17 September 2007
- atopic dermatitis;
- T cells
Background Blockade of lymphocyte function associated antigen-1 (LFA-1) is proving successful in the management of psoriasis and other inflammatory skin conditions including atopic dermatitis (AD), but the dependence of allergen-specific CD4+ T-cell function on LFA-1 has not been studied extensively.
Objectives We sought to investigate the potential ability of LFA-1 inhibition to influence keratinocyte presentation of allergen to specific T-helper (Th) 2 cell clones.
Methods Using human leucocyte antigen class II tetrameric complexes, we generated Der p 1-specific DRB1*1501-restricted CD4+ T-cell lines (n = 5) and clones (n = 4) from the peripheral blood of five adults with AD.
Results Using doses of anti-LFA-1 present in vivo, we observed significant inhibition (P < 0·05) of allergen-specific CD4+ T-cell production of interleukin-4 with such inhibition occurring during presentation of allergen by keratinocytes.
Conclusions These data show that at doses present in vivo, LFA-1 blockade inhibits keratinocyte presentation to allergen-specific Th2 cells, suggesting one mechanism through which anti-LFA-1 may be beneficial therapeutically.